Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Explaining differential vulnerability to climate change: A social science review.

Thomas K, Hardy RD, Lazrus H, Mendez M, Orlove B, Rivera-Collazo I, Roberts JT, Rockman M, Warner BP, Winthrop R.

Wiley Interdiscip Rev Clim Change. 2019 Mar-Apr;10(2):e565. doi: 10.1002/wcc.565. Epub 2018 Dec 7. Review.

2.

A Sharing Meanings Approach for Interdisciplinary Hazards Research.

Hardy RD.

Risk Anal. 2018 Oct 10. doi: 10.1111/risa.13216. [Epub ahead of print]

PMID:
30368856
3.

Fatal outcomes in family transmission of Mycoplasma pneumoniae.

Kannan TR, Hardy RD, Coalson JJ, Cavuoti DC, Siegel JD, Cagle M, Musatovova O, Herrera C, Baseman JB.

Clin Infect Dis. 2012 Jan 15;54(2):225-31. doi: 10.1093/cid/cir769. Epub 2011 Nov 3.

4.

Synthesis and distribution of CARDS toxin during Mycoplasma pneumoniae infection in a murine model.

Kannan TR, Coalson JJ, Cagle M, Musatovova O, Hardy RD, Baseman JB.

J Infect Dis. 2011 Nov 15;204(10):1596-604. doi: 10.1093/infdis/jir557. Epub 2011 Sep 28.

5.

Efficacy of increasing dosages of clarithromycin for treatment of experimental Mycoplasma pneumoniae pneumonia.

Tagliabue C, Techasaensiri C, Torres JP, Katz K, Meek C, Kannan TR, Coalson JJ, Esposito S, Principi N, Leff R, Baseman JB, Hardy RD.

J Antimicrob Chemother. 2011 Oct;66(10):2323-9. doi: 10.1093/jac/dkr306. Epub 2011 Jul 25.

6.

Variation in colonization, ADP-ribosylating and vacuolating cytotoxin, and pulmonary disease severity among mycoplasma pneumoniae strains.

Techasaensiri C, Tagliabue C, Cagle M, Iranpour P, Katz K, Kannan TR, Coalson JJ, Baseman JB, Hardy RD.

Am J Respir Crit Care Med. 2010 Sep 15;182(6):797-804. doi: 10.1164/rccm.201001-0080OC. Epub 2010 May 27.

7.

Mycoplasma pneumoniae Community Acquired Respiratory Distress Syndrome toxin expression reveals growth phase and infection-dependent regulation.

Kannan TR, Musatovova O, Balasubramanian S, Cagle M, Jordan JL, Krunkosky TM, Davis A, Hardy RD, Baseman JB.

Mol Microbiol. 2010 Jun 1;76(5):1127-41. doi: 10.1111/j.1365-2958.2010.07092.x. Epub 2010 Feb 28.

8.

Analysis of pulmonary inflammation and function in the mouse and baboon after exposure to Mycoplasma pneumoniae CARDS toxin.

Hardy RD, Coalson JJ, Peters J, Chaparro A, Techasaensiri C, Cantwell AM, Kannan TR, Baseman JB, Dube PH.

PLoS One. 2009 Oct 27;4(10):e7562. doi: 10.1371/journal.pone.0007562.

9.

Tigecycline therapy significantly reduces the concentrations of inflammatory pulmonary cytokines and chemokines in a murine model of Mycoplasma pneumoniae pneumonia.

Salvatore CM, Techasaensiri C, Tagliabue C, Katz K, Leos N, Gomez AM, McCracken GH, Hardy RD.

Antimicrob Agents Chemother. 2009 Apr;53(4):1546-51. doi: 10.1128/AAC.00979-08. Epub 2009 Jan 12.

10.

The impact of steroids given with macrolide therapy on experimental Mycoplasma pneumoniae respiratory infection.

Tagliabue C, Salvatore CM, Techasaensiri C, Mejias A, Torres JP, Katz K, Gomez AM, Esposito S, Principi N, Hardy RD.

J Infect Dis. 2008 Oct 15;198(8):1180-8. doi: 10.1086/591915.

11.

Prevalence of and risk factors for methicillin-resistant Staphylococcus aureus (MRSA) nasal colonization in HIV-infected ambulatory patients.

Cenizal MJ, Hardy RD, Anderson M, Katz K, Skiest DJ.

J Acquir Immune Defic Syndr. 2008 Aug 15;48(5):567-71. doi: 10.1097/QAI.0b013e31817e9b79.

PMID:
18645516
12.

DMSA renal scans and the top-down approach to urinary tract infection.

Hardy RD, Austin JC.

Pediatr Infect Dis J. 2008 May;27(5):476-7. doi: 10.1097/INF.0b013e318168d26f.

PMID:
18401288
13.

Intranasal interleukin-12 therapy inhibits Mycoplasma pneumoniae clearance and sustains airway obstruction in murine pneumonia.

Salvatore CM, Fonseca-Aten M, Katz-Gaynor K, Gomez AM, Hardy RD.

Infect Immun. 2008 Feb;76(2):732-8. Epub 2007 Nov 26.

14.

Systemic cytokine profile in children with community-acquired pneumonia.

Michelow IC, Katz K, McCracken GH, Hardy RD.

Pediatr Pulmonol. 2007 Jul;42(7):640-5.

PMID:
17534977
15.
16.

Respiratory tract infection with Mycoplasma pneumoniae in interleukin-12 knockout mice results in improved bacterial clearance and reduced pulmonary inflammation.

Salvatore CM, Fonseca-Aten M, Katz-Gaynor K, Gomez AM, Mejias A, Somers C, Chavez-Bueno S, McCracken GH, Hardy RD.

Infect Immun. 2007 Jan;75(1):236-42. Epub 2006 Oct 30.

17.

Effect of clarithromycin on cytokines and chemokines in children with an acute exacerbation of recurrent wheezing: a double-blind, randomized, placebo-controlled trial.

Fonseca-Aten M, Okada PJ, Bowlware KL, Chavez-Bueno S, Mejias A, Rios AM, Katz K, Olsen K, Ng S, Jafri HS, McCracken GH, Ramilo O, Hardy RD.

Ann Allergy Asthma Immunol. 2006 Oct;97(4):457-63.

PMID:
17069099
18.

Pneumonia and septicemia caused by Burkholderia thailandensis in the United States.

Glass MB, Gee JE, Steigerwalt AG, Cavuoti D, Barton T, Hardy RD, Godoy D, Spratt BG, Clark TA, Wilkins PP.

J Clin Microbiol. 2006 Dec;44(12):4601-4. Epub 2006 Oct 18.

19.

Treatment of experimental chronic pulmonary mycoplasmosis.

Fonseca-Aten M, Rios AM, Mejias A, Chavez-Bueno S, Katz K, Gomez AM, Ramilo O, McCracken GH, Hardy RD.

Int J Antimicrob Agents. 2006 Sep;28(3):253-8. Epub 2006 Aug 7.

PMID:
16891098
20.
21.

Evaluation of LBM415 (NVP PDF-713), a novel peptide deformylase inhibitor, for treatment of experimental Mycoplasma pneumoniae pneumonia.

Fonseca-Aten M, Salvatore CM, Mejías A, Ríos AM, Chávez-Bueno S, Katz K, Gómez AM, McCracken GH Jr, Hardy RD.

Antimicrob Agents Chemother. 2005 Oct;49(10):4128-36.

22.

Microbiologic and immunologic evaluation of a single high dose of azithromycin for treatment of experimental Mycoplasma pneumoniae pneumonia.

Ríos AM, Fonseca-Aten M, Mejías A, Chávez-Bueno S, Katz K, Gómez AM, McCracken GH Jr, Ramilo O, Hardy RD.

Antimicrob Agents Chemother. 2005 Sep;49(9):3970-3.

23.

Hormonal treatment of a recurrent granulosa cell tumor of the ovary: case report and review of the literature.

Hardy RD, Bell JG, Nicely CJ, Reid GC.

Gynecol Oncol. 2005 Mar;96(3):865-9. Review.

PMID:
15721440
24.

Mycoplasma pneumoniae induces host-dependent pulmonary inflammation and airway obstruction in mice.

Fonseca-Aten M, Ríos AM, Mejías A, Chávez-Bueno S, Katz K, Gómez AM, McCracken GH Jr, Hardy RD.

Am J Respir Cell Mol Biol. 2005 Mar;32(3):201-10. Epub 2004 Dec 30.

PMID:
15626776
25.

It is safe to stop antiretroviral therapy in patients with preantiretroviral CD4 cell counts >250 cells/microL.

Skiest DJ, Morrow P, Allen B, McKinsey J, Crosby C, Foster B, Hardy RD.

J Acquir Immune Defic Syndr. 2004 Nov 1;37(3):1351-7.

PMID:
15483464
26.

IL-4-independent pathways exacerbate methacholine-induced airway hyperreactivity during mycoplasma respiratory disease.

Woolard MD, Hardy RD, Simecka JW.

J Allergy Clin Immunol. 2004 Sep;114(3):645-9.

PMID:
15356571
27.

Impact of cethromycin (ABT-773) therapy on microbiological, histologic, immunologic, and respiratory indices in a murine model of Mycoplasma pneumoniae lower respiratory infection.

Ríos AM, Mejías A, Chávez-Bueno S, Fonseca-Aten M, Katz K, Hatfield J, Gómez AM, Jafri HS, McCracken GH Jr, Ramilo O, Hardy RD.

Antimicrob Agents Chemother. 2004 Aug;48(8):2897-904.

29.

Respiratory syncytial virus induces pneumonia, cytokine response, airway obstruction, and chronic inflammatory infiltrates associated with long-term airway hyperresponsiveness in mice.

Jafri HS, Chavez-Bueno S, Mejias A, Gomez AM, Rios AM, Nassi SS, Yusuf M, Kapur P, Hardy RD, Hatfield J, Rogers BB, Krisher K, Ramilo O.

J Infect Dis. 2004 May 15;189(10):1856-65. Epub 2004 Apr 29.

PMID:
15122522
30.

Management and outcome of children with skin and soft tissue abscesses caused by community-acquired methicillin-resistant Staphylococcus aureus.

Lee MC, Rios AM, Aten MF, Mejias A, Cavuoti D, McCracken GH Jr, Hardy RD.

Pediatr Infect Dis J. 2004 Feb;23(2):123-7.

PMID:
14872177
31.

Antimicrobial and immunologic activities of clarithromycin in a murine model of Mycoplasma pneumoniae-induced pneumonia.

Hardy RD, Rios AM, Chavez-Bueno S, Jafri HS, Hatfield J, Rogers BB, McCracken GH, Ramilo O.

Antimicrob Agents Chemother. 2003 May;47(5):1614-20.

32.

Garenoxacin (BMS-284756) and moxifloxacin in experimental meningitis caused by vancomycin-tolerant pneumococci.

Rodriguez-Cerrato V, McCoig CC, Saavedra J, Barton T, Michelow IC, Hardy RD, Bowlware K, Iglehart J, Katz K, McCracken GH Jr.

Antimicrob Agents Chemother. 2003 Jan;47(1):211-5.

33.

A randomized, double-blind, placebo-controlled trial of dexamethasone in severe respiratory syncytial virus (RSV) infection: effects on RSV quantity and clinical outcome.

Buckingham SC, Jafri HS, Bush AJ, Carubelli CM, Sheeran P, Hardy RD, Ottolini MG, Ramilo O, DeVincenzo JP.

J Infect Dis. 2002 May 1;185(9):1222-8. Epub 2002 Apr 16.

PMID:
12001038
34.

Mycoplasma pneumoniae induces chronic respiratory infection, airway hyperreactivity, and pulmonary inflammation: a murine model of infection-associated chronic reactive airway disease.

Hardy RD, Jafri HS, Olsen K, Hatfield J, Iglehart J, Rogers BB, Patel P, Cassell G, McCracken GH, Ramilo O.

Infect Immun. 2002 Feb;70(2):649-54.

35.

BMS-284756 in experimental cephalosporin-resistant pneumococcal meningitis.

Rodriguez-Cerrato V, Ghaffar F, Saavedra J, Michelow IC, Hardy RD, Iglehart J, Olsen K, McCracken GH Jr.

Antimicrob Agents Chemother. 2001 Nov;45(11):3098-103.

36.

Pharmacodynamics and bactericidal activity of moxifloxacin in experimental Escherichia coli meningitis.

Rodriguez-Cerrato V, McCoig CC, Michelow IC, Ghaffar F, Jafri HS, Hardy RD, Patel C, Olsen K, McCracken GH Jr.

Antimicrob Agents Chemother. 2001 Nov;45(11):3092-7.

37.

Elevated cytokine and chemokine levels and prolonged pulmonary airflow resistance in a murine Mycoplasma pneumoniae pneumonia model: a microbiologic, histologic, immunologic, and respiratory plethysmographic profile.

Hardy RD, Jafri HS, Olsen K, Wordemann M, Hatfield J, Rogers BB, Patel P, Duffy L, Cassell G, McCracken GH, Ramilo O.

Infect Immun. 2001 Jun;69(6):3869-76.

38.

The sign of Leser-Trélat.

Hardy RD, Duvic M, Bleyer WA.

Med Pediatr Oncol. 1997 Mar;28(3):234-7. No abstract available.

PMID:
9024524
39.

Chick embryo lethal orphan (CELO) virus: some physical and immunological properties.

Potter CW, Oxford JS, Downie JC, Attwood MM, Hardy RD.

Virology. 1971 May;44(2):418-24. No abstract available.

PMID:
4105260
40.

Location of spore and vegatative antigens of Bacillus cereus by means of ferritin-labelled antibodies.

Thomson RO, Walker PD, Hardy RD.

Nature. 1966 May 14;210(5037):760-1. No abstract available.

PMID:
4163998

Supplemental Content

Loading ...
Support Center